Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hilde Azijn"'
Autor:
Johan Vingerhoets, Bjorn Daems, Lotke Tambuyzer, Steven Nijs, Gaston Picchio, Marie Pierre de Béthune, Hilde Azijn
Publikováno v:
AIDS Research and Human Retroviruses. 26:1197-1205
The randomized, placebo-controlled Phase III DUET studies enrolled treatment-experienced, HIV-1-infected patients. We examined the genotypic and phenotypic changes at endpoint relative to baseline, including the emergence of individual reverse transc
Autor:
Steven Nijs, Johan Vingerhoets, Goedele De Smedt, Sandra De Meyer, Inge Dierynck, Hilde Azijn, Laurence T. Rimsky, Gaston Picchio, Marie-Pierre de Béthune, Lotke Tambuyzer
Publikováno v:
AIDS Research and Human Retroviruses. 26:621-624
Etravirine (ETR) has previously shown potent in vitro activity against different primary HIV-1 isolates and demonstrated durable efficacy in treatment-experienced, HIV-1-infected patients in the Phase III DUET studies. The antiviral activity and effi
Autor:
Lotke Tambuyzer, Johan Vingerhoets, Gaston Picchio, Hilde Azijn, Sandra De Meyer, Monika Peeters, Andrew F. Hill
Publikováno v:
AIDS. 24:921-924
Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experie
Autor:
Annemie Hoogstoel, Goedele De Smedt, Monika Peeters, Steven Nijs, Johan Vingerhoets, Marie-Pierre de Béthune, Hilde Azijn, Brian Woodfall, Gaston Picchio, Lotke Tambuyzer
Publikováno v:
AIDS. 24:503-514
Objective: To refine the genotypic and phenotypic correlates of response to the nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine resistance-associated mutations (RAMs) and clinical cutoffs (C
Autor:
Robin J. Shattock, Sarah Harman, Hilde Azijn, Jeremy Nuttall, P. Manlow, D. Perumal, MP de Béthune, Naomi Armanasco, Joseph Romano, Patricia S. Fletcher
Publikováno v:
Antimicrobial Agents and Chemotherapy. 53:487-495
Heterosexual transmission of human immunodeficiency virus (HIV) remains the major route of infection worldwide; thus, there is an urgent need for additional prevention strategies, particularly strategies that could be controlled by women, such as top
Autor:
Guenter Kraus, Johan Vingerhoets, Lotke Tambuyzer, Pierre Lecocq, Hilde Azijn, Marie-Pierre de Béthune, Laurence T. Rimsky, Gaston Picchio
Publikováno v:
Antiviral Therapy. 14:103-109
Background Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of antiretroviral therapy for HIV type-1 (HIV-1)-infected patients. Development of NNRTI resistance can lead to treatment failure and is conferred by the p
Autor:
Koen Andries, Rudi Pauwels, Marie-Pierre de Béthune, Els Fransen, Dirk Jochmans, Liesbet Smeulders, Hilde Azijn, Johan Vingerhoets, Inky De Baere
Publikováno v:
Journal of virology
TMC125 is a potent new investigational nonnucleoside reverse transcriptase inhibitor (NNRTI) that is active against human immunodeficiency virus type 1 (HIV-1) with resistance to currently licensed NNRTIs. Sequential passage experiments with both wil
Autor:
Dominique Louis Nestor Ghislain Surleraux, Anik Peeters, Sandra De Meyer, Rudi Wilfried Jan Pauwels, Moses Prabu-Jeyabalan, Piet Wigerinck, Celia A. Schiffer, Geert M. E. Pille, Hilde Azijn, Louis J. R. Maes, Herman Augustinus De Kock, Sandrine Marie Helene Vendeville, Wim Gaston Verschueren, Marie-Pierre de Béthune, Nancy M. King
Publikováno v:
Journal of medicinal chemistry
On the basis of structural data gathered during our ongoing HIV-1 protease inhibitors program, from which our clinical candidate TMC114 9 was selected, we have discovered new series of fused heteroaromatic sulfonamides. The further extension into the
Autor:
Michael Joseph Kukla, Theo Thielemans, Rudi Pauwels, Donald Ludovici, Hilde Azijn, Johan Vingerhoets, Koen Andries, Paul Adriaan Jan Janssen, Marie-Pierre de Béthune, Jan Heeres, Corte Bart De
Publikováno v:
Antimicrobial agents and chemotherapy
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent inhibitors of human immunodeficiency virus type 1 (HIV-1); however, currently marketed NNRTIs rapidly select resistant virus, and cross-resistance within the class is extensive. A par
Autor:
Bart De Corte, Hong Ye, Chih Y. Ho, Donald William Ludovici, Marc René De Jonge, Hilde Azijn, Paul J. Lewi, Michael J. Kukla, Paul Adriaan Jan Janssen, Mark A. Lichtenstein, Lucien Maria Henricus Koymans, Koen Jeanne Alfons Van Aken, Edward Arnold, Rudi Pauwels, Marie Pierre de Béthune, Frederik Frans Desire Daeyaert, Robert W. Kavash, Koen Andries, Jan Heeres, Kalyan Das
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 11:2235-2239
The synthesis and anti-HIV-1 activity of a series of diarylpyrimidines (DAPYs) are described. Several members of this novel class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) are extremely potent against both wild-type and a panel of c